Quintrio
Home

LABORATORY ANALYTICAL INSTRUMENTS

Bio-Rad Laboratories, Inc. Class B

BIO.B

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $366.60 – $369.70
Volume 8
Market cap —

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$10.49B
Price / earnings
10.25×
Price / book
1.38×
Price / sales
4.05×
EV / sales
4.33×
EV / EBITDA
69.86×

Profitability

Earnings per share
$38.04
Return on assets
9.49%
Return on equity
13.45%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.16×
Current ratio
3.18×
Quick ratio
2.37×
Cash ratio
0.48×

Cash flow

Price / cash flow
22.4×
Price / free cash flow
31.87×
Free cash flow
$329.1M

Ratios use trailing-twelve-month financials and market data as of Nov 9, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BIO.B, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$656.4M$651M$592.1M$693.2M$653M$651.6M$585.4M$667.5M
Cost of revenue$327.8M$305.2M$282.7M$348M$309.6M$306.3M$279.4M$325.6M
Gross profit$328.6M$345.8M$309.4M$345.2M$343.4M$345.3M$306M$341.9M
Selling, general and administrative$257.1M$212M$212.4M$221M$206.8M$207.7M$208.8M$204M
Research and development$71.4M$61.2M$62.9M$70.3M$71.3M$60.5M$73.5M$79.6M
Total operating expenses$378.3M$273.2M$275.3M$291.3M$278.1M$268.2M$282.3M$283.6M
Operating income-$49.7M$72.6M$34.1M$53.9M$65.3M$77.1M$23.7M$58.3M
Interest expense-$12.3M-$12.1M-$12.3M-$12.1M-$12.3M-$12.6M-$12M-$12.2M
Income before taxes$538.7M$542.1M-$689.8M$929.2M-$431.1M$414M$83.4M-$908.9M
Income taxes$80.1M$170.7M-$162.7M$209.2M-$89.2M$96.2M$19.4M-$193.1M
Net income$458.6M$371.4M-$527.1M$720M-$341.9M$317.8M$64M-$715.8M
Net income attributable to common shareholders$458.6M$371.4M-$527.1M$720M-$341.9M$317.8M$64M-$715.8M
EBITDA$100K$72.6M$34.1M$53.9M$65.3M$77.1M$23.7M$58.3M
Basic earnings per share$17.13$13.89-$19.55$26.70-$12.70$11.67$2.29-$25.57
Diluted earnings per share$17.02$13.85-$19.55$26.65-$12.70$11.67$2.29-$25.62

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026: Capture the $4.5 Billion Market by 2032 | Features Competitive Intelligence on Thermo Fisher, Beckman Coulter, Bio-Rad, Qiagen and Merck

The global cell lysis and cell fractionation market is projected to grow from $2.8 billion in 2025 to $4.5 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in biotechnology, personalized medicine, proteomics, genomics research, and biopharmaceutical development. Emerging technologies including automation, microfluidics, AI/ML integration, and single-cell analysis capabilities are reshaping the market landscape.

Zacks Investment Research

Bio-Rad Laboratories (BIO) Q3 Earnings Top Estimates

Bio-Rad Laboratories reported Q3 2026 earnings of $2.65 per share, beating consensus estimates of $2.61, but revenues of $656.4 million missed expectations by 0.83%. The stock has outperformed the S&P 500 by 13.1% year-to-date. Despite the earnings beat, Bio-Rad received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. The Medical-Products industry ranks in the bottom 37% of Zacks industries.

Zacks Investment Research

Neogen (NEOG) Q1 Earnings and Revenues Beat Estimates

Neogen reported quarterly earnings of $0.08 per share, beating consensus estimates of $0.05 and marking a 60% earnings surprise. The company also exceeded revenue expectations with $222.8 million, up from $209.19 million year-over-year. Despite strong performance, Neogen's Medical-Products industry ranks in the bottom 35% of Zacks industries. The stock has gained 86.1% year-to-date and holds a Zacks Rank #2 (Buy) rating.

GlobeNewswire Inc.

Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation

The global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR.

GlobeNewswire Inc.

Europe Point of Care Diagnostics Market Size and Forecast, 2021 - 2031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR

Europe's Point of Care (POC) Diagnostics Market is projected to grow from US$8.9 billion in 2024 to US$21.4 billion by 2031, with a 13.4% CAGR driven by rapid testing innovation, molecular diagnostics advancement, and increasing prevalence of infectious and chronic diseases. Germany leads the regional market, supported by strong healthcare infrastructure and public health initiatives. Key players include Siemens AG, Abbott Laboratories, Roche, bioMerieux, Bio-Rad, QIAGEN, Nova Biomedical, Polymer Technology Systems, and Danaher Corp.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.